Can-Fite BioPharma’s (CANF) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Can-Fite BioPharma (NYSE:CANF) in a research report report published on Tuesday morning, MarketBeat reports. The firm currently has a $2.50 target price on the stock. HC Wainwright also issued estimates for Can-Fite BioPharma’s FY2026 earnings at $0.00 EPS, FY2027 earnings at $0.00 EPS, FY2028 earnings at $0.00 EPS and FY2029 earnings at $0.00 EPS.

Separately, D. Boral Capital reiterated a “buy” rating and issued a $11.00 price target on shares of Can-Fite BioPharma in a research note on Tuesday, September 16th. Two research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Can-Fite BioPharma has an average rating of “Buy” and a consensus price target of $6.75.

Can-Fite BioPharma Stock Down 0.2%

Shares of CANF opened at $0.42 on Tuesday. Can-Fite BioPharma has a twelve month low of $0.41 and a twelve month high of $2.38. The company has a market capitalization of $1.47 million, a P/E ratio of -0.23 and a beta of 1.01. The firm has a 50 day moving average of $0.57 and a 200 day moving average of $0.83.

Hedge Funds Weigh In On Can-Fite BioPharma

A hedge fund recently raised its stake in Can-Fite BioPharma stock. Rhumbline Advisers increased its stake in Can-Fite BioPharma Ltd. (NYSE:CANF) by 42.4% during the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 38,268 shares of the company’s stock after purchasing an additional 11,388 shares during the quarter. Rhumbline Advisers owned approximately 1.08% of Can-Fite BioPharma worth $57,000 at the end of the most recent quarter. 21.00% of the stock is currently owned by institutional investors and hedge funds.

Can-Fite BioPharma Company Profile

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.